Try our mobile app

General information

Country: UNITED STATES

Sector: Drug Manufacturers — General

Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products for humans and animals. The Company products are sold in countries around the world. Eli Lilly products include neuroscience, endocrine, anti-infectives, cardiovascular agents, oncology, and animal health products.
Website: lilly.com


  • Bad financial results growth rate -10.5% (average between last period year over year growth for revenue and EBITDA), there is slowdown compared to average historical growth rates (10.0%)
  • Dividend yield for the last twelve months 0.6%
  • Free cash flow yield -0.4% (LTM)
  • Share price is 304.0% higher than minimum and 7.9% lower than maximum for the last 3 years
  • The company is overvalued by EV / LTM EBITDA multiple compared to target level (91.2x vs
    )
  • Fundamental value created in LTM (estimate)
  • For the last 3 months insiders sold company shares on $465.5 mln (-0.071% of cap.)

Key Financials (Download financials)

Ticker: LLY
Share price, USD:  (-2.2%)729.4425
year average price 577.38  


year start price 385.24 2023-04-21

min close price 376.27 2023-04-26

max close price 792.28 2024-03-04

current price 745.95 2024-04-19
Common stocks: 903 782 000

Dividend Yield:  0.6%
FCF Yield LTM: -0.4%
EV / LTM EBITDA: 91.2x
EV / EBITDA annualized: 200.9x
Last revenue growth (y/y):  36.8%
Last growth of EBITDA (y/y):  -57.8%
Historical revenue growth:  12.1%
Historical growth of EBITDA:  7.8%
Target EV / EBITDA (hist percentile):
Fundamental value created in LTM:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 659 257
Net Debt ($m): 17 761
EV (Enterprise Value): 677 018
EBITDA LTM ($m): 7 420
EV / LTM EBITDA: 91.2x
Price to Book: 62.6x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2024-04-18Proactive Investors

Big pharma: cautious optimism ahead of earnings season - analysts

2024-04-18Zacks Investment Research

Eli Lilly's (LLY) Tirzepatide Meets Goals in Sleep Apnea Studies

2024-04-18The Motley Fool

2 Growth Stocks That Turned $10,000 Into More Than $100,000 in Just 10 Years

2024-04-17Schwab Network

Eli Lilly's Chart Gets Another Boost from Obesity Drug

2024-04-17Investopedia

Eli Lilly's Weight-Loss Treatment Found To Help Those With Sleep Apnea

2024-04-17CNBC

Most doses of Eli Lilly's Zepbound, Mounjaro in short supply through June, FDA says

2024-04-17Fast Company

Eli Lilly's weight-loss drug Zepbound might help cure your sleep apnea

2024-04-17Forbes

Weight Loss Drug Zepbound May Reduce Sleep Apnea, Eli Lilly Says

2024-04-17Schaeffers Research

Eli Lilly Stock Pops on Drug Efficacy for Sleep Apnea

2024-04-17Reuters

Most doses of Lilly's Mounjaro and Zepbound in limited availability, US FDA says
More information for subscribed users:
detailed calculation of
Potential and Created Value,
website traffic data